Cencora, Inc.

NYSE:COR Stock Report

Market Cap: US$44.4b

Cencora Valuation

Is COR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of COR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: COR ($227.64) is trading below our estimate of fair value ($654.45)

Significantly Below Fair Value: COR is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for COR?

Key metric: As COR is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for COR. This is calculated by dividing COR's market cap by their current earnings.
What is COR's PE Ratio?
PE Ratio29.2x
EarningsUS$1.51b
Market CapUS$44.42b

Price to Earnings Ratio vs Peers

How does COR's PE Ratio compare to its peers?

The above table shows the PE ratio for COR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average24.2x
CAH Cardinal Health
21.9x7.4%US$28.2b
MCK McKesson
28.2x15.0%US$72.4b
HSIC Henry Schein
29.1x26.7%US$9.4b
PDCO Patterson Companies
17.6x13.0%US$2.7b
COR Cencora
29.2x14.8%US$44.4b

Price-To-Earnings vs Peers: COR is expensive based on its Price-To-Earnings Ratio (29.2x) compared to the peer average (24.2x).

Price to Earnings Ratio vs Industry

How does COR's PE Ratio compare vs other companies in the US Healthcare Industry?

4 CompaniesPrice / EarningsEstimated GrowthMarket Cap
NEUE NeueHealth
1.2xn/aUS$38.38m
IDXG Interpace Biosciences
2.5xn/aUS$12.19m
FZMD Fuse Medical
2.2xn/aUS$8.67m
ETAO.F ETAO International
n/an/aUS$51.00
No more companies available in this PE range
COR 29.2xIndustry Avg. 21.9xNo. of Companies11PE01632486480+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: COR is expensive based on its Price-To-Earnings Ratio (29.2x) compared to the US Healthcare industry average (22.8x).

Price to Earnings Ratio vs Fair Ratio

What is COR's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

COR PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio29.2x
Fair PE Ratio34.1x

Price-To-Earnings vs Fair Ratio: COR is good value based on its Price-To-Earnings Ratio (29.2x) compared to the estimated Fair Price-To-Earnings Ratio (34.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst COR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$227.64
US$266.34
+17.0%
8.3%US$302.00US$230.00n/a15
Dec ’25US$251.55
US$266.14
+5.8%
7.7%US$292.00US$230.00n/a15
Nov ’25US$234.27
US$257.32
+9.8%
7.6%US$287.00US$215.00n/a16
Oct ’25US$224.23
US$259.92
+15.9%
7.5%US$287.00US$215.00n/a16
Sep ’25US$239.57
US$262.05
+9.4%
7.5%US$287.00US$215.00n/a16
Aug ’25US$244.46
US$260.98
+6.8%
7.7%US$287.00US$215.00n/a16
Jul ’25US$223.53
US$255.98
+14.5%
9.0%US$280.00US$194.00n/a16
Jun ’25US$226.57
US$255.33
+12.7%
9.3%US$280.00US$194.00n/a15
May ’25US$229.20
US$254.84
+11.2%
8.6%US$280.00US$194.00n/a16
Apr ’25US$243.00
US$247.84
+2.0%
10.4%US$270.00US$183.00n/a16
Mar ’25US$237.03
US$247.00
+4.2%
10.7%US$270.00US$183.00n/a15
Feb ’25US$236.92
US$234.73
-0.9%
12.6%US$267.00US$183.00n/a15
Jan ’25US$205.38
US$211.71
+3.1%
6.7%US$235.00US$176.00n/a14
Dec ’24US$204.09
US$208.92
+2.4%
6.3%US$223.00US$176.00US$251.5513
Nov ’24US$187.23
US$207.23
+10.7%
8.4%US$225.00US$162.00US$234.2713
Oct ’24US$179.97
US$206.23
+14.6%
8.1%US$225.00US$162.00US$224.2313
Sep ’24US$174.96
US$206.36
+17.9%
7.9%US$225.00US$162.00US$239.5714
Aug ’24US$189.10
US$194.79
+3.0%
8.9%US$213.00US$149.00US$244.4614
Jul ’24US$192.43
US$187.13
-2.8%
8.1%US$208.00US$149.00US$223.5315
Jun ’24US$172.59
US$186.20
+7.9%
7.6%US$207.00US$149.00US$226.5715
May ’24US$166.79
US$181.47
+8.8%
7.1%US$205.00US$149.00US$229.2015
Apr ’24US$160.11
US$181.20
+13.2%
6.9%US$201.00US$149.00US$243.0015
Mar ’24US$156.51
US$181.62
+16.0%
7.2%US$201.00US$149.00US$237.0313
Feb ’24US$161.05
US$181.17
+12.5%
7.9%US$201.00US$149.00US$236.9212
Jan ’24US$165.71
US$176.82
+6.7%
7.0%US$195.00US$148.00US$205.3811
Dec ’23US$171.63
US$177.45
+3.4%
6.2%US$195.00US$155.00US$204.0911

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/17 07:53
End of Day Share Price 2024/12/17 00:00
Earnings2024/09/30
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cencora, Inc. is covered by 39 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Gregory BolanAvondale Partners
Eric ColdwellBaird